Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB-001 in Children and Adolescents With 22q11 Deletion Syndrome
NCT05290493Phase 2Completed
- Sponsor
- Nobias Therapeutics
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of fasoracetam in 22q11.2 deletion syndrome (22q11.2DS) (2 arms), sponsored by Nobias Therapeutics. Primary endpoint: Safety and Tolerability of NB-001 at 6 weeks. Started Feb 2022; status: completed.
02
Drugs
fasoracetam
03
Conditions
22q11.2 deletion syndrome (22q11.2DS)
Beyond the preview
Go deeper on NCT05290493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05290493.